The tibial neuromodulation devices market is projected to grow significantly, with an estimated value of USD 97.7 million in 2022 and expected to surpass USD 230.7 million by 2032. This growth reflects a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2022 to 2032.
Rising Demand for Non-Invasive Solutions Driving Growth
The tibial neuromodulation devices market is experiencing robust growth as patients and healthcare providers increasingly prefer non-invasive and minimally invasive treatments for managing overactive bladder and associated urological conditions. These devices offer effective symptom relief with minimal risks compared to traditional surgical interventions.
Technological Innovations Boost Adoption
Ongoing advancements in tibial neuromodulation technology, such as portable and user-friendly devices, are enhancing the efficacy and accessibility of treatment. Integration with digital health platforms for remote monitoring and personalized care is further driving market adoption.
A Detailed Full Report – https://www.futuremarketinsights.com/reports/percutaneous-tibial-neuromodulation-devices-market
Future Outlook: Expanding Accessibility in Emerging Markets
Expanding healthcare infrastructure and rising awareness in emerging economies are expected to provide significant growth opportunities for the market. Government initiatives promoting advanced medical technologies will also contribute to increased adoption.
The Tibial Neuromodulation Devices Market is poised for sustained growth, offering innovative and effective solutions to address unmet needs in urological healthcare worldwide.
Market Drivers
- Increasing Prevalence of Urinary Disorders: The rising incidence of urinary conditions, such as overactive bladder, is driving demand for effective treatment options like tibial neuromodulation devices.
- Growing Awareness and Acceptance: There is increasing awareness among healthcare providers and patients regarding the benefits of neuromodulation therapies, leading to higher adoption rates.
- Technological Advancements: Continuous innovations in tibial neuromodulation technologies are enhancing treatment efficacy and patient comfort, further boosting market growth.
- Minimally Invasive Procedures: The preference for minimally invasive treatment options is encouraging the use of tibial neuromodulation devices as a non-surgical alternative for managing urinary disorders.
- Aging Population: An increasing elderly population that is more susceptible to urinary disorders is significantly contributing to the demand for tibial neuromodulation therapies.
Regional Insights
- The market is expected to see substantial growth in regions with advanced healthcare infrastructure and increasing healthcare expenditures, particularly in North America and Europe.
Challenges
- High Cost of Devices: The cost associated with tibial neuromodulation devices may limit accessibility for some patients, particularly those without adequate insurance coverage.
- Limited Awareness in Emerging Markets: Awareness and acceptance of tibial neuromodulation therapies may be lower in emerging markets, hindering market penetration.
Competitive Landscape
Who are some of the Key Market Players in the Tibial Neuromodulation Devices Market?
The neuromodulation devices market is consolidated, with the top four firms accounting for more than 90% of the market in 2022. Medtronic’s extensive portfolio, along with strong brand awareness, widespread regional presence, and a solid distribution network, is responsible for propelling the business to market leadership in 2022.
The key market players profiled in the report include Cogentix Medical, Palex Medical SA, and Medtronic plc. Rainbow Medical Group. The key players in this market adopted product launch, partnership, and expansion as their key strategies to meet the changing consumer demands.
Recent Developments in the Tibial Neuromodulation Devices Market:
- ElectroCore Inc., a commercial-stage medical device startup, acquired US FDA approval for their gammaCore non-invasive vagus nerve stimulation (nVNS) device in November 2018. In the United States, the device was approved as an additional therapy for the treatment of cluster headaches.
- SenTiva, a vagus nerve stimulation device from LivaNova PLC, was approved by the US Food and Drug Administration in October 2017 for the treatment of epilepsy. The gadget is approved for drug-resistant epilepsy patients over the age of four.
Key Companies Profiled
Cogentix Medical, Palex Medical SA, Medtronic plc. Rainbow Medical Group.
Key Market Segments in the Tibial Neuromodulation Devices Market
By Application:
- Faecal Incontinence
- Overactive Bladder
By End User:
- Hospital
- Ambulatory Surgical centers
- Clinics
- Specialty Care Unit
- Others
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa (MEA)
- Europe
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
